Biotech chief quits as firm hunts for missing millions
- {{x.value}}
{{ twilioFailed ? 'SMS Code Failed to Send…' : 'Enter verification code' }}
{{ completedStep1 ? 'Authentication & Security' : content.trialHeading.replace('{0}', user.FirstName) }}
{{ content.upgradeHeading.replace('{0}', user.FirstName) }}
The email address you entered is registered with InvestSMART
Please login to continue
We have sent you an email with the details of your registration.
Looks you are already a member. Please enter your password to proceed
{{ upgradeCTAText }}
Updating information
Please wait ...
Your membership to InvestSMART Group recently failed to renew.
Please make sure your payment details are up to date to continue your membership.
Having trouble renewing?
Please contact Member Services on support@investsmart.com.au or 1300 880 160
You've recently updated your payment details.
It may take a few minutes to update your subscription details, during this time you will not be able to view locked content.
If you are still having trouble viewing content after 10 minutes, try logging out of your account and logging back in.
Still having trouble viewing content?
Please contact Member Services on support@investsmart.com.au or 1300 880 160
Please click on the ACTIVATE button to activate your Intelligent Investor 15-day free trial
Please click on the ACTIVATE button to finalise your membership
Unsuccessful registration
Registration for this event is available only to Eureka Report members. View our membership page for more information.
Registration for this event is available only to Intelligent Investor members. View our membership page for more information.
- You are already registered for this event.
- This event is already full.
- Please select a quantity for at least one ticket.
- {{ i }}
Forgotten password
Please enter your email address below to request a new password
- Verify your email address by clicking on the link we sent to {{user.Email}}
- You now have free access, we look forward to helping you on your financial journey.
The company told the stock exchange on Monday it had received Ms Ogru's resignation, effective Thursday, July 18.
While the company would not say how much was at stake, it is understood between $3 million and $5 million has been misappropriated.
Phosphagenics, which is worth $107.1 million, invests in new technology that delivers cosmetic and pharmaceutical products such as insulin through the skin.
Property records show Phosphagenics last week slapped caveats over four properties owned by Ms Ogru, together worth more than $2.3 million.
Phosphagenics claims it has an interest in Ms Ogru's land holdings, including her $586,000 family home in Melbourne suburb Wheelers Hill, "as chargee pursuant to an equitable charge".
If the caveats are not removed by a court, they will give Phosphagenics the right to share in the proceeds of any sale of the properties.
In addition to the Wheelers Hill property, Phosphagenics has laid claim to a $321,000 unit in Mount Waverley, a $350,000 house in Noble Park and a $1 million beachside house in Portarlington, on Port Phillip Bay.
The caveats were registered on Wednesday and Thursday - the day Ms Ogru resigned her position at Phosphagenics.
The company appointed a legal and accounting firm to investigate the irregularities when it noticed them in June.
A spokesman for the company said it expected to announce the findings of the investigation to the stockmarket on Wednesday.
The company does not need to report the missing funds to police as it is not required to do so under Victorian law.
Executive director and joint chief executive Harry Rosen, who is based in the company's New York office, has assumed the role of sole chief executive in Ms Ogru's absence.
Call 1300 880 160
Start a chat
Schedule a call
